Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleroderma lung: pathogenesis, evaluation and current therapy.

Jacob M van Laar1, Jan Stolk, Alan Tyndall

  • 1Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. j.m.van_laar@lumc.nl

Drugs
|May 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individualised treatment effect prediction: the benefit of initial biological treatment in early rheumatoid arthritis.

EULAR rheumatology open·2026
Same author

Five years of the Digital Rheumatology Network: insights and future directions.

EULAR rheumatology open·2026
Same author

Recent developments in the use of biomarkers as diagnostic tools in patients with systemic lupus erythematosus: a narrative review.

EULAR rheumatology open·2026
Same author

Amplification of genetic and metabolic factors in alpha-1 antitrypsin deficiency.

Hepatology (Baltimore, Md.)·2026
Same author

A composite biomarker score to predict modified Rodnan skin score in systemic sclerosis: insight from autologous stem cell transplantation international scleroderma trial.

Arthritis research & therapy·2025
Same author

Visualizing the codevelopment of structural and immune cells in the human fetal lung using imaging mass cytometry.

American journal of physiology. Lung cellular and molecular physiology·2025
Same journal

Ecnoglutide: First Approvals.

Drugs·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
See all related articles

Systemic sclerosis (scleroderma) frequently affects the lungs, causing disabling symptoms. Early diagnosis and treatment of scleroderma lung disease, including interstitial lung disease and pulmonary hypertension, can improve patient outcomes.

Area of Science:

  • Rheumatology and Pulmonology
  • Systemic autoimmune diseases
  • Fibrotic and vasculopathic processes

Background:

  • Systemic sclerosis (scleroderma) is a rare, disabling autoimmune disease of unknown origin.
  • Pulmonary involvement, including interstitial lung disease and pulmonary hypertension, is common and contributes to significant morbidity and mortality.
  • Dyspnoea in scleroderma patients can stem from various causes, necessitating a thorough diagnostic work-up.

Purpose of the Study:

  • To outline the diagnostic approach for dyspnoea in scleroderma patients.
  • To highlight the impact of lung disease on scleroderma prognosis.
  • To discuss current and emerging therapeutic strategies for scleroderma lung disease.

Main Methods:

  • Comprehensive evaluation including 6-minute walk test, pulmonary function testing, and high-resolution thoracic CT.

Related Experiment Videos

  • Cardiovascular assessment with ECG, echocardiography, and potentially right-heart catheterisation for pulmonary hypertension.
  • Optional bronchoalveolar lavage for further characterization.

    • Main Results:

    • Scleroderma lung disease significantly increases morbidity and mortality, particularly with reduced diffusion capacity or forced vital capacity.
    • Early detection of lung involvement is crucial for timely intervention.
    • Emerging treatments show promise in managing scleroderma lung disease.

    Conclusions:

    • Scleroderma lung disease is a major contributor to poor outcomes in systemic sclerosis.
    • A systematic diagnostic approach is essential to identify and manage pulmonary complications.
    • New therapeutic agents offer potential for improved management and survival in patients with scleroderma lung disease.